Profile data is unavailable for this security.
About the company
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)773.17m
- Net income in HKD-1.14bn
- Incorporated2017
- Employees665.00
- LocationEverest Medicines Ltd16/F., CITIC Pacific Plaza,1168 West Nanjing Road, JingAn DistrictSHANGHAI 200041ChinaCHN
- Websitehttps://www.everestmedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Traditional Chinese Med Hldg CoLtd | 18.06bn | 59.15m | 11.43bn | 16.75k | 193.18 | 0.4928 | 9.13 | 0.6329 | 0.0118 | 0.0118 | 3.59 | 4.61 | 0.4578 | 1.61 | 1.90 | 1,078,205.00 | 0.0576 | 3.48 | 0.0839 | 5.24 | 47.59 | 54.69 | 0.1258 | 7.39 | 1.80 | 7.65 | 0.1437 | 21.27 | -8.90 | 2.89 | -95.79 | -49.14 | -15.28 | -48.82 |
| Luye Pharma Group Ltd | 6.63bn | 516.29m | 12.71bn | 5.15k | 24.63 | 0.821 | 8.09 | 1.92 | 0.1372 | 0.1372 | 1.76 | 4.12 | 0.22 | 2.32 | 2.78 | 1,287,725.00 | 2.34 | 1.98 | 3.84 | 3.16 | 66.72 | 68.37 | 10.64 | 8.04 | 1.15 | 3.01 | 0.4001 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 4.07bn | 528.13m | 13.25bn | 4.86k | 25.09 | 1.42 | 13.78 | 3.25 | 0.6002 | 0.6002 | 4.63 | 10.58 | 0.2959 | 1.76 | 1.78 | 838,133.30 | 3.84 | 4.72 | 5.36 | 6.95 | 75.03 | 76.98 | 12.96 | 15.49 | 1.54 | 43.06 | 0.208 | 3.14 | -40.84 | -9.76 | -75.78 | -24.12 | -6.71 | -- |
| Everest Medicines Ltd | 773.17m | -1.14bn | 22.19bn | 665.00 | -- | 4.93 | -- | 28.70 | -3.55 | -3.55 | 2.41 | 13.74 | 0.1317 | 10.89 | 3.42 | 1,162,664.00 | -19.41 | -29.28 | -21.61 | -31.67 | 74.56 | -- | -147.36 | -1,040.86 | 2.52 | -- | 0.1238 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| HUTCHMED (China) Ltd | 4.95bn | 296.17m | 22.28bn | 1.81k | 75.29 | 3.73 | 56.20 | 4.50 | 0.3394 | 0.3394 | 5.67 | 6.84 | 0.4935 | 6.93 | 4.53 | 2,731,648.00 | 2.99 | -9.55 | 4.36 | -13.77 | 44.64 | 39.84 | 6.06 | -20.32 | 2.70 | -- | 0.1042 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Duality Biotherapeutics Inc | -100.00bn | -100.00bn | 25.34bn | 170.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.66 | -- | -193.82 | -- | -- | -- |
| Simcere Pharmaceutical Group Ltd | 7.26bn | 802.15m | 25.84bn | 6.58k | 32.89 | 3.36 | 22.05 | 3.56 | 0.3174 | 0.3174 | 2.88 | 3.11 | 0.5934 | 2.17 | 2.48 | 1,102,603.00 | 6.56 | 8.74 | 8.65 | 12.42 | 80.25 | 78.53 | 11.05 | 15.60 | 1.79 | 3.60 | 0.1461 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.05bn | 2.91bn | 25.84bn | 17.00k | 8.88 | 1.64 | 7.21 | 1.72 | 1.60 | 1.60 | 8.29 | 8.66 | 0.5874 | 3.29 | 5.78 | 885,503.50 | 11.35 | 9.37 | 16.93 | 14.54 | 44.21 | 44.33 | 19.32 | 15.06 | 1.55 | -- | 0.1794 | 26.01 | 0.1387 | 10.39 | -1.54 | 32.89 | 37.25 | 45.96 |
| Shanghai Henlius Biotech Inc | 6.26bn | 897.67m | 28.42bn | 3.52k | 31.67 | 8.62 | 21.74 | 4.54 | 1.65 | 1.65 | 11.52 | 6.07 | 0.5585 | 2.07 | 7.02 | 1,781,815.00 | 8.00 | -3.21 | 15.78 | -5.76 | 73.10 | 72.50 | 14.33 | -7.87 | 0.3544 | 10.04 | 0.5476 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
| Zai Lab Ltd | 3.28bn | -1.98bn | 29.10bn | 1.87k | -- | 4.46 | -- | 8.86 | -1.96 | -1.96 | 3.23 | 5.87 | 0.387 | 3.35 | 6.11 | -- | -23.32 | -33.80 | -30.56 | -39.12 | 63.62 | 64.07 | -60.26 | -186.77 | 3.09 | -- | 0.1762 | -- | 49.59 | 98.38 | 23.17 | -- | 32.19 | -- |
| China Medical System Holdings Ltd | 8.17bn | 1.77bn | 29.96bn | 6.14k | 16.83 | 1.68 | 14.62 | 3.67 | 0.7297 | 0.7297 | 3.37 | 7.32 | 0.4175 | 2.91 | 6.31 | 1,330,691.00 | 9.02 | 16.35 | 10.05 | 18.70 | 72.60 | 75.03 | 21.60 | 32.20 | 5.24 | -- | 0.0499 | 40.16 | -6.79 | 4.22 | -32.54 | -3.75 | 6.01 | -2.60 |
| Grand Pharmaceutical Group Ltd | 11.64bn | 2.47bn | 32.90bn | 11.99k | 13.16 | 1.97 | 11.08 | 2.83 | 0.7046 | 0.7046 | 3.33 | 4.70 | 0.4902 | 3.56 | 11.01 | 971,460.10 | 10.38 | 10.40 | 14.08 | 14.24 | 57.86 | 61.04 | 21.18 | 22.80 | 1.01 | -- | 0.212 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
Data as of Jul 11 2025. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD
5.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Jul 2025 | 3.85m | 1.18% |
| GF Fund Management Co., Ltd.as of 31 Dec 2024 | 3.15m | 0.97% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 2.38m | 0.73% |
| Ping An Fund Management Co., Ltd.as of 31 Dec 2024 | 2.19m | 0.67% |
| China Asset Management Co., Ltd.as of 31 Dec 2024 | 1.60m | 0.49% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2024 | 1.57m | 0.48% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 827.50k | 0.25% |
| E Fund Asset Management Co. Ltd.as of 31 Dec 2024 | 785.00k | 0.24% |
| SSgA Funds Management, Inc.as of 02 Jul 2025 | 417.50k | 0.13% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 389.50k | 0.12% |
More ▼
Data from 31 Dec 2024 - 03 Jul 2025Source: FactSet Research Systems Inc.
